Hypoxia-inducible factor-1α obstructs a wnt signaling pathway by inhibiting the hARD1-mediated activation of β-catenin

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5177-5184

  Lim, Ji Hong ^a   Chun, Yang Sook ^a   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMIDE; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HUMAN ARREST DEFECTIVE 1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LITHIUM CHLORIDE; UNCLASSIFIED DRUG; WNT1 PROTEIN; ARD1A PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P21; T CELL FACTOR 4; T CELL FACTOR PROTEIN; WNT PROTEIN;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL STRAIN HEK293; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL CULTURE; CELL HYPOXIA; CELL PROLIFERATION; CELL STRAIN HCT116; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ACETYLATION; ACETYLTRANSFERASES; BETA CATENIN; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 48549098557     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6234     Document Type: Article

References (48)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
2. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996;56:5754-7.
3. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
4. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2002;3:721-32.
6. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359-69.
7. Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004;36:530-9.
8. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
9. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
10. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-206.
11. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
12. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
13. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 2002;111:709-20.
14. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71.
15. Willert K, Nusse R. β-Catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 1998;8:95-102.
16. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev 2006;20:1394-404.
17. Gavert N, Ben-Ze'ev A. β-Catenin signaling in biological control and cancer. J Cell Biochem 2007;102:820-8.
18. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007;17:45-51.
19. Kaidi A, Williams AC, Paraskeva C. Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007;9:210-7.
20. Whiteway M, Szostak JW. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell 1985;43:483-92.
21. Park EC, Szostak JW. ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J 1995;11:2087-93.
22. Sugiura N, Adams SM, Corriveau RA. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J Biol Chem 2003;278:40113-20.
23. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J 2005;386:433-43.
24. Bilton R, Trottier E, Pouysségur J, Brahimi-Horn MC. ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol 2006;16:616-21.
25. Kim SH, Park JA, Kim JH, et al. Characterization of ARD1 variants in mammalian cells. Biochem Biophys Res Commun 2006;340:422-7.
26. Chun KH, Cho SJ, Choi JS, Kim SH, Kim KW, Lee SK. Differential regulation of splicing, localization and stability of mammalian ARD1235 and ARD1225 isoforms. Biochem Biophys Res Commun 2007;353:18-25.
27. Arnesen T, Kong X, Evjenth R, et al. Interaction between HIF-1 a (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 α. FEBS Lett 2005;579:6428-32.
28. Lim JH, Park JW, Chun YS. Human arrest defective 1 acetylates and activates β-catenin, promoting lung cancer cell proliferation. Cancer Res 2006;66:10677-82.
29. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wildtype p53 by hypoxia-inducible factor 1α. Nature 1998;392:405-8.
30. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004;23:1949-56.
31. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW. A new HIF-1 α variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci 2001;114:4051-61.
32. Chun YS, Lee KH, Choi E, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1α isoform: implications for tumor promotion. Cancer Res 2003;63:8700-7.
33. Lee KH, Choi E, Chun YS, Kim MS, Park JW. Differential responses of two degradation domains of HIF-1α to hypoxia and iron deficiency. Biochimie 2006;88:163-9.
34. Kim HL, Yeo EJ, Chun YS, Park JW. A domain responsible for HIF-1α degradation by YC-1, a novel anticancer agent. Int J Oncol 2006;29:255-60.
35. van de Wetering M, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50.
36. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980-5.
37. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005;12:5-10.
38. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45.
39. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003;283:17-21.
40. Levy L, Wei Y, Labalette C, et al. Acetylation of β-catenin by p300 regulates β-catenin-Tcf4 interaction. Mol Cell Biol 2004;24:3404-14.
41. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-5.
42. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
43. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
44. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003;3:75-88.
45. Lim JH, Park JW, Kim MS, Park SK, Johnson RS, Chun YS. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1α. Mol Pharmacol 2006;70:1856-65.
46. Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007;67:1735-43.
47. Yi CH, Sogah DK, Boyce M, Degterev A, Christofferson DE, Yuan J. A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol 2007;179:619-26.
48. Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-α-acetyltransferase complex. Oncogene 2006;25:4350-60.